joining And thank quarter Thanks. call. first everyone earnings XXXX to and Alex, Therapeutics’ you Inhibikase for thank you,
As field year, diligently preclinical This investor disease. month, clinical as an educational development we the example, we leading Parkinson's kicked advance in of extend for off to disorders our worked as thought to together host movement have in we programs the leadership and KOLs brought our well event. past
this our the AD/PD conferences quarter, presented as Conference and We as Generation results well where rationale c-Abl Summit, Next disease. Annual studies targeting behind we Phase for highlighted we also medical Parkinson's in including the IkT-XXXXXX participated the where Inhibitors past from multiple Phase Kinase X Xb
anticipate milestones. quarter, in Parkinson's. Xa our achieving the in we look importantly, the expect As dose to second Most Phase number study IkT-XXXXXX in key of we we ahead a first patients for
IkT-XXXXXX in IkT-XXXPro CML, of Atrophy In we MSA. Chronic preclinical at also Multiple application IND or phase our Systems as Myelogenous Leukemia, data expect least one from report for for as addition, stable well filing study or
development pipeline that website. under our of for accessed event our be key Educational our in The event Together therapeutic leaders, with we a regulatory our Before hosted landscape preclinical competitive replay month. patients. the clinical need, our into Parkinson's I cover programs, Events watch of to we dive to as want everyone & potential strategy Investor current as the for and and last option IkT-XXXXXX IR encourage I disease Presentations unmet well as the section can opinion
non-receptor an Kinase is highly our selective program, lead c-Abl inhibitor. IkT-XXXXXX a with So now let me Tyrosine Abelson start IkT-XXXXXX.
accumulate ability to in was profile the Toxicology and barrier and Animal As including, designs. brain. to predictable a to the have XXXXXX, the remember, Studies, these low-toxicity designed have Studies you blood-brain Chronic may confirm cross
subjects or randomized, IkT-XXXXXX that study. trial cohort data dosing The levels evaluating disease. the Phase currently safety assessing The Parkinson's from this The X:X the of is of cohort a we escalating with Pharmacokinetics aggregates and three nervous X system. the escalation of from the extension healthy study. and suggested in of volunteers similar, and tolerability consistent are motility is non-motor In to mild Parkinson's endpoints. and IkT-XXXXXX trial moderately and penetrates the plans Xb and is Conference, patients to dose our safety, at motor across that placebo-controlled older patient and first further seven-day dose tolerability, pharmacology exploratory We and pharmacokinetics profile of and patients central study closely volunteers advanced IkT-XXXXXX also data a presented also, at IkT-XXXXXX as met in is AD/PD measure Alzheimer's from Diseases function alpha-synuclein gut was that the study of Conference. Phase groups March, the in suggesting evaluating
eight expect in of second six to cohort dosed have complete second and patients the in cohort this We the quarter.
and expect medical of year. the disease later present We meeting additional on the the on this from effects data Parkinson's comment to study measures a at
a is of cannot for seven different While small at potential doses. number the blinded, the still draw we any benefit IkT-XXXXXX based trial the dosing days of on about conclusions of patients
a results Phase seven working believe Phase a are same that not IkT-XXXXXX a does of of the the We we far pharmacology dosed our when outcomes, we patient's for advance dubbed study of is to continue that healthy patients treatment support thus Trial in disease XXX and and the age. of Parkinson's, for in Based to on Phase have the therapeutic Xa IkT-XXXXXX potential The and study. as subjects into diligently with yet these The the trial XXX for similar Phase determined days also X disease and randomized, X:X that trial and to worsen that and up to treatment endpoints, will Parkinson's brain Xa Xb hierarchy IkT-XXXXXX non-motor disease-modifying studies end XX-week outside seen diagnosed clinician the IkT-XXXXXX safety a to Parkinson's and symptomatic exploratory doses IkT-XXXXXX points. whether a of have will in that reduction patient leads measure inside the treatment. patients of safety and not three will of tolerability and pathogenic be dosing IkT-XXXXXX clearance or need as evaluate will reported evaluate double-blind function as secondary using of motor who outcomes aggregate alpha-synuclein of the to with progressed
first activating quarter. We and the the are announcing of forward look second sites currently process the in in dosing in to patients clinical
efforts. Turning our now to preclinical
We are programs in work two our leverage advancing that neurodegeneration.
such Myeloid Leukemia. for have Mesylate The first is stable-phase matinib of designed a better Imatinib-sensitive potentially as formulation Chronic cancers, our we IkT-XXXPro, safer, which as tolerated prodrug treatment
studies conducting submission the the are investigational stability IND application for quarter. for submit expect necessary We to submission this drug IND the package and new
study the later the we proceed discussions intend Following it may XXX(b)(X) FDA, the regulatory and commence bioequivalence to pathway. the with with receipt other accordance studies of in
our the multiple work ph for XXXXXX treatment Finally, preclinical atrophy. we evaluating system are potential continuing of
that Union, inhibition have As we expect systems. one to the studies which essential to and you these model autonomic MSA on is disease. benefit evaluating has study of is Similar could two Parkinson's, into fourth to full are slow of of approximately a affects may and to equivalent the of neurons. may currently quarter by These The clinical we dysfunction people halt this nervous effect. and at in model a FDA MSA the movement in subject a therapeutic characterized pathological Xa a whether in MSA that no or from European results the bodies progression remember, therapeutic Phase in one second XXXX. affects models c-Abl Depending study degeneration animal rare, treatments agreement US there studies beneficial XXXXXX approved of and preclinical lead administration XX,XXX may in both and from least neurodegenerative aggregation, with progressive cell advance in and disorder rapidly to alpha-synuclein the regulatory MSA, of data preliminary XXXX. readouts quarter report animal indicates IkT-XXXXXX are
let over to call the Joe? Frattaroli, Now CFO, turn me Joe financials. to review our the
